Checkpoint Blockade and Acquired Humoral Immune Dysregulation: Emerging Evidence for Antibody Deficiency During...

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Immune checkpoint inhibitors (ICIs) like anti-PD-1/PD-L1 therapies enhance antitumor T-cell activity.
• The PD-1/PD-L1 pathway is crucial for immune homeostasis, tolerance, and B-cell development.
• Inborn errors in PD-1/PD-L1 signaling suggest its role beyond simple immune inhibition.

Purpose of the Study:

• To review evidence linking PD-1/PD-L1 blockade to humoral immune dysfunction.
• To investigate the impact of ICIs on B-cell biology, antibody responses, and vaccine immunogenicity.
• To explore the potential for acquired antibody deficiency secondary to ICI therapy.

Main Methods:

• Synthesis of existing literature on PD-1/PD-L1 biology and ICI effects.
• Analysis of studies examining B-cell populations (e.g., age-associated B cells) and antibody responses in patients receiving ICIs.
• Review of clinical data on vaccine responses and infection susceptibility during ICI therapy.

Main Results:

• PD-1/PD-L1 blockade is linked to altered class-switched memory B-cell biology and antibody responses.
• Emerging evidence suggests ICIs may expand age-associated B cells, potentially impairing neutralizing antibody production.
• Current data do not establish the incidence or causality of ICI-induced antibody deficiency, supporting a model of heterogeneous humoral remodeling.

Conclusions:

• Prolonged PD-1/PD-L1 blockade may induce or reveal acquired humoral immune dysfunction in susceptible individuals.
• The spectrum of effects ranges from enhanced immune activation to antibody failure and secondary antibody deficiency.
• Future research should include comprehensive immunological assessments to elucidate ICI-induced humoral changes and their clinical implications.